Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: onogi h. Haematologica. 2024 Oct 1;109(10):3357-3362. doi: 10.3324/haematol.2023.283992. Haematologica. 2024. PMID: 38841789 Free PMC article. Clinical Trial. No abstract available.
Alterations in prefrontal cortical neuregulin-1 levels in post-pubertal rats with neonatal ventral hippocampal lesions.
Watanabe K, Nakagawasai O, Kanno SI, Mitazaki S, Onogi H, Takahashi K, Watanabe KI, Tan-No K, Ishikawa M, Srivastava LK, Quirion R, Tadano T. Watanabe K, et al. Among authors: onogi h. Front Behav Neurosci. 2022 Dec 22;16:1008623. doi: 10.3389/fnbeh.2022.1008623. eCollection 2022. Front Behav Neurosci. 2022. PMID: 36620856 Free PMC article.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: onogi h. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. Haematologica. 2023. PMID: 36200417 Free PMC article.
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.
Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K. Utsunomiya A, et al. Among authors: onogi h. Cancer Sci. 2022 Aug;113(8):2778-2787. doi: 10.1111/cas.15431. Epub 2022 Jun 7. Cancer Sci. 2022. PMID: 35579212 Free PMC article.
74 results